sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_9182> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_9182> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01234> ;
    a rdf:Statement ;
    rdfs:label "primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance acute adrenocortical insufficiency hydrocortisone or cortisone is the drug of choice mineralocorticoid supplementation may be necessary particularly when synthetic analogs are used preoperatively and in the event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected congenital adrenal hyperplasia as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in post traumatic osteoarthritis during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus pemphigus control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in bronchial asthma severe acute and chronic allergic and inflammatory processes involving the eye such as herpes zoster ophthalmicus to tide the patient over a critical period of the disease in ulcerative colitis systemic therapy symptomatic sarcoidosis acquired autoimmune hemolytic anemia for palliative management of leukemias and lymphomas in adults to induce diuresis or remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy trichinosis with neurologic or myocardial involvement" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01234> bl:category bl:Drug .
}